Veracyte Announces Launch of New Afirma Xpression Atlas at 2018 AACE Congress
The Afirma Xpression Atlas detects 761 DNA variants and 130 RNA fusion pairs in over 500 genes that have been linked to thyroid cancer. In some cases, these gene alterations have demonstrated association with more aggressive thyroid cancers or with higher-stage disease.
“For patients who are already going to surgery for suspected thyroid
cancer, the Afirma Xpression Atlas provides additional genomic
information that physicians and patients may use in decisions about the
surgical approach,” said
The gene variants and fusion partners in the Afirma Xpression Atlas were derived from the thyroid literature and from The Cancer Genome Atlas (TCGA). The RNA-sequencing based panel is offered as an extension to Veracyte’s market-leading Afirma Genomic Sequencing Classifier (GSC), which is widely used to identify benign nodules among those deemed indeterminate by cytopathology so that patients can avoid unnecessary surgery.
“In tandem with our Afirma GSC, the Afirma Xpression Atlas provides
physicians with the most comprehensive and evidence-based genomic
information available to inform diagnosis, stratify thyroid cancer risk
and, for those who are diagnosed with cancer, aid in therapeutic
More information about Afirma data being presented at the AACE meeting can be found at Veracyte’s booth (#707) or at www.veracyte.com/AACE2018.
Veracyte’s Afirma solution provides a comprehensive solution for
physicians evaluating patients with potentially cancerous thyroid
nodules. The Afirma Genomic Sequencing Classifier combines RNA
sequencing data with machine learning to identify patients with benign
thyroid nodules among those with indeterminate cytopathology results in
order to avoid unnecessary surgery and preserve the thyroid. Since the
commercial introduction of Afirma in 2011,
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, our belief that our genomic tests will transform the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis; statements regarding our Afirma Xpression Atlas platform, which we plan to introduce soon; and Afirma’s ability to significantly improve patient care and reduce healthcare costs. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the benefits of our tests, the applicability of clinical results to actual outcomes; the laws and regulations applicable to our business, including potential regulation by the Food and Drug Administration or other regulatory bodies; our ability to sell our Afirma tests and successfully transition to our next-generation Afirma GSC; our ability to successfully achieve and maintain adoption of and reimbursement for our products; the amount by which use of our products are able to reduce invasive procedures and misdiagnosis, and reduce healthcare costs; the occurrence and outcomes of clinical studies; and other risks set forth in our filings with the Securities and Exchange Commission, including the risks set forth in our quarterly report on Form 10-Q for the quarter ended March 31, 2018. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise, except as required by law.